Choose your location

Stragen,
A Global Healthcare Player

History

1990

Stragen is founded by Jean-Luc Tétard.

2004

Stragen expands into Denmark and establishes the affiliate Stragen Nordic A/S.

2005

Stragen extends its presence to Finland and the United Kingdom.

2006

Introduction of our first contraceptive product.

2008

Launch of Piperacillin/Tazobactam.

2016

Stragen expands into France.

2016

Launch of Urapidil Caps.

2020

Stragen expands into Italy and Spain.

2021

Investment company ARCHIMED acquires Stragen.

2021

Stragen acquires OHRE Pharma to strengthen its expertise in critical care.

Our history

Founded in 1990 in Geneva, Switzerland, Stragen (STRAtegic GENerics) initially established itself in the pharmaceutical market as an active pharmaceutical ingredient trading platform and later as an international generic drug manufacturer specializing in niche medications.

Our mission

We are committed to improving patient and healthcare professional access to high added-value niche products for priority treatments. Our goal is to provide innovative therapeutic solutions that specifically address the requirements and unmet needs of hospital-based healthcare professionals.

Our vision

We aspire to become the favored partner of healthcare professionals by facilitating and supporting access to niche medications. We aim to create an environment where every patient can benefit from quality treatments, offering innovative solutions and playing a key role in healthcare improvement.

European Expertise

Benefit from a Worldwide Distribution Network

We work with our extensive network of dynamic, qualified, and diverse partners to ensure that our products are efficiently and safely delivered to healthcare professionals and patients at a fair price.

01

Premium distribution: Stragen operates in over 60 countries, covering 77% of the European population.

02

A reliable leading European partner in critical Care with 20 years of hospital expertise.

03

Worldwide Pharmaceutical Product Registration Expertise: Over 400 marketing authorizations.

04

Comprehensive understanding of country specific regulations at european level.

05

Pharmacovigilance Services overseen by an Experienced Team of Scientific and Medical Experts.

Our Team

Jean-Yves Desmottes: Chief Executive Officer

Antoine Tétard: Vice President Sales-BD

Ludovic Alonzi: Deputy Chief Executive Officer

Virginie Chazottes: Human Resources Manager

Fabrice Schurdevin : Business Development Director

Virginie Puech: W&CH business Manager

Héloise Deliquiet: Legal Manager

Bruno Girard Candau: Technical Director

Jacky Biry: Financial Manager

Antoine Bevillard: Regulatory Affairs Manager